Scinovex
review Open AccessTop 1% cited

A review of the clinical pharmacology of methamphetamine

Addiction · 2009 · Vol. 104(7) · pp. 1085–1099
Christopher CruickshankKyle R. Dyer

Abstract

The mean elimination half-life for methamphetamine is approximately 10 hours, with considerable inter-individual variability in pharmacokinetics. Direct effects at low-to-moderate methamphetamine doses (5-30 mg) include arousal, positive mood, cardiac stimulation and acute improvement in cognitive domains such as attention and psychomotor coordination. At higher doses used typically by illicit users (> or =50 mg), methamphetamine can produce psychosis. Its hypertensive effect can produce a number of acute and chronic cardiovascular complications. Repeated use may induce neurotoxicity, associated with prolonged psychiatric symptoms, cognitive impairment and an increased risk of developing Parkinson's disease. Abrupt cessation of repeated methamphetamine use leads to a withdrawal syndrome consisting of depressed mood, anxiety and sleep disturbance. Acute withdrawal lasts typically for 7-10 days, and residual symptoms associated with neurotoxicity may persist for several months.

Neurotransmitter Receptor Influence on BehaviorForensic Toxicology and Drug AnalysisPsychedelics and Drug StudiesMethamphetaminePsychomotor learningMedicineMoodPsychosisNeurotoxicityAnxietyDepression (economics)EuphoriantAdverse effect

MeSH terms

Central Nervous System StimulantsCardiovascular DiseasesDose-Response Relationship, DrugHalf-LifeHumansMethamphetamineRisk FactorsSubstance Withdrawal SyndromeRandomized Controlled Trials as TopicAmphetamine-Related Disorders

Funding

  • National Health and Medical Research Council
  • National Medical Research Council
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.